STAT+: By narrow margin, FDA advisory panel concludes Amylyx ALS drug hasn’t proven effectiveness
For archived live coverage of the hearing of the FDA’s advisory panel, click here.
By a narrow margin, an independent panel of advisers to the Food and Drug Administration on Wednesday concluded that data from a single trial of an experimental drug developed by Amylyx Pharmaceuticals were not sufficient to conclude the therapy was an effective treatment against ALS.
Continue to STAT+ to read the full story…
